Menarini Stemline licenses Georgiamune GIM-621 oral cancer immunotherapy in deal worth up to $1.1 billion

Menarini's Stemline Therapeutics has secured worldwide rights to Georgiamune's investigational oral cancer immunotherapy GIM-621 in a licensing agreement worth up to $1.1 billion.

The exclusive collaboration gives Stemline global development, manufacturing and commercialisation rights to GIM-621, a preclinical first-in-class oral small-molecule immunotherapy being investigated for multiple solid tumours.

Georgiamune will receive $45 million in combined upfront and near-term payments and may earn additional preclinical, development, regulatory and commercial milestones, bringing potential consideration to $1.1 billion plus royalties.

Field	Content
Article Type	Deals
Companies	Menarini Group; Stemline Therapeutics; Georgiamune
Deal Type	Exclusive worldwide licensing and collaboration agreement
Licensor	Georgiamune
Licensee	Stemline Therapeutics, a Menarini Group company
Licensed Asset	GIM-621
Therapeutic Area	Oncology
Target Indications	Multiple solid tumours under investigation
Therapeutic Modality	Oral small-molecule immunotherapy
Asset Description	Investigational first-in-class oral immuno-oncology agent
Development Stage	Preclinical
Licensed Rights	Global development, manufacturing and commercialisation
Territory	Worldwide
Upfront and Near-Term Payments	$45 million combined; individual amounts not disclosed
Total Potential Deal Value	Up to $1.1 billion plus royalties
Additional Milestones	Preclinical, development, regulatory and commercial milestones; individual amounts not disclosed
Royalties	Additional royalties; rates not disclosed
Announcement Date	22 October 2026
What Happened	Menarini subsidiary Stemline Therapeutics entered an exclusive global licensing and collaboration agreement for Georgiamune's GIM-621.
Why It Matters	The transaction adds a novel investigational oral immunotherapy programme to Menarini's oncology pipeline and provides Georgiamune with funding and potential downstream payments.
Strategic Rationale	Stemline gains worldwide rights to advance GIM-621 while Georgiamune benefits from a pharmaceutical development and commercialisation partner.
Key Takeaway	The agreement carries up to $1.1 billion in potential consideration plus royalties, but GIM-621 remains preclinical and most payments depend on future milestones.
What to Watch	Preclinical validation, investigational new drug preparation, first-in-human development, target indications and milestone achievements.
Primary Source	Menarini Group
Primary Source URL	https://www.menarini.com/en-us/news/news-detail/georgiamune-and-menarini-group-enter-exclusive-global-license-and-collaboration-agreement-for-gim-621-a-first-in-class-oral-immuno-oncology-agent.html
Relevant Date	22 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com